ACHV vs. RIGL, VSTM, EBS, VNDA, IRWD, XOMA, CDXS, SGMO, LXRX, and RGLS
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Emergent BioSolutions (EBS), Vanda Pharmaceuticals (VNDA), Ironwood Pharmaceuticals (IRWD), XOMA (XOMA), Codexis (CDXS), Sangamo Therapeutics (SGMO), Lexicon Pharmaceuticals (LXRX), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences vs.
Rigel Pharmaceuticals (NASDAQ:RIGL) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment.
Rigel Pharmaceuticals currently has a consensus target price of $36.80, indicating a potential upside of 100.11%. Achieve Life Sciences has a consensus target price of $15.75, indicating a potential upside of 443.10%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Rigel Pharmaceuticals.
Rigel Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rigel Pharmaceuticals had 3 more articles in the media than Achieve Life Sciences. MarketBeat recorded 5 mentions for Rigel Pharmaceuticals and 2 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 1.07 beat Rigel Pharmaceuticals' score of 0.89 indicating that Achieve Life Sciences is being referred to more favorably in the news media.
Rigel Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.67, indicating that its stock price is 67% more volatile than the S&P 500.
66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 9.0% of Rigel Pharmaceuticals shares are owned by insiders. Comparatively, 2.0% of Achieve Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Rigel Pharmaceuticals received 133 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 68.98% of users gave Rigel Pharmaceuticals an outperform vote.
Rigel Pharmaceuticals has a net margin of 2.46% compared to Achieve Life Sciences' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of -14.80% beat Achieve Life Sciences' return on equity.
Summary
Rigel Pharmaceuticals beats Achieve Life Sciences on 11 of the 18 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ACHV) was last updated on 3/28/2025 by MarketBeat.com Staff
